Bobby Han, MD
Clinical Associate Professor
Division of Rheumatology
Sites of Practice: 
Roosevelt Clinic
University of Washington Medical Center

Faculty Information

Education & Training: 
Seoul National University
Seoul, South Korea
Residency and Chief Residency in Internal Medicine
Western Pennsylvania Hospital
Pittsburgh PA
Fellowship in Rheumatology
University of Texas, Southwestern Medical School
Dallas, TX
(206) 543-3414
Mailing Address: 

1959 NE Pacific Street
Box 356428
Seattle, WA 98195-6428

Dr. Han's Clinical Trials

Research & Clinical Interests
Research Interests: 

Dr. Han is studying biomarkers which could help define subtypes of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). His research has shown that 1. several chemokines including CXCL13 are predictive biomarkers of the therapeutic response in RA, 2. the CD27-CD70 pathway is upregulated in patients with RA and SLE and the molecules related to this pathway are potentially useful biomarkers. He is involved in designing and implementing clinical trials which would address clinically relevant questions in rheumatology.


    Han BK, Kuzin I, Gaughan JP, Olsen NJ,  Bottaro A. Baseline CXCL10 and CXCL13 levels are Predictive biomarkers for Tumor Necrosis Factor Inhibitor therapy in Patients with moderate to severe Rheumatoid Arthritis: A Pilot, Prospective Study. Arthritis Res Ther. 2016 Apr 22;18(1):93.

    Han BK, Olsen NJ, Bottaro A. The CD27-CD70 pathway and Pathogenesis of Autoimmune Disease. Semin Arthritis Rheum. 2016 Feb;45(4):496-501

    Becker A, Dao K, Han BK, Kornu R, Lakhanpal S, Mobley A,  Li Q, Lian Y, Wu T, Reimold A, Olsen N, Karp D, Chowdhury F, Farrar J, Satterthwaite A, Mohan C, Lipsky P, Wakeland E, Davis L. SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature. PLoS ONE. 2013; 8(6): e67003

    Han BK, Bhatia R, Traisak P, Milcarek B, Hunter K, Schorr C, Eid H, Feinstein D, Cronin P, Kolasinski SL. Clinical Presentations and Outcomes of Systemic Lupus Erythematosus Patients with Infection admitted to Intensive Care Unit. Lupus. 2013;22(7):690-6

    Han BK, Yachoui R, Yi K. Are Ocular Complications of a High dose Glucocorticoid treatment Appropriately Monitored in Patients with Rheumatic diseases? Rheumatol Int. 2013;33(11):2951-2

    Bennett R, Friend R, Jones K, Ward R, Han BK, Ross R. Revised Fibromyalgia Impact Questionnaire (FIQR): Validation and Properties. Arthritis Res Ther. 2009; 11(4):R120

    Han BK, White A, Dao K, Karp D, Wakeland E, Davis L. Increased Prevalence of Activated CD70+CD4+ T Cells in the Periphery of Patients with Systemic Lupus Erythematosus. Lupus. 2005; 14(8): 598-606